Sigma raises A$297 million to acquire rights to BMS products
This article was originally published in Scrip
Executive Summary
Australia's Sigma Pharmaceuticals has raised A$297 million ($256 million) in a one-for-three rights offer to help acquire an established brand portfolio and a manufacturing facility from Bristol-Myers Squibb.